Ratings Astec LifeSciences Limited

Equities

ASTEC

INE563J01010

Market Closed - NSE India S.E. Other stock markets 05:13:47 03/05/2024 pm IST			5-day change	1st Jan Change
1,232 ^INR	-0.59%		+1.02%	+12.49%

03/05	Astec Lifesciences' CFO Resigns	MT
02/05	Astec LifeSciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Agricultural Chemicals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ASTEC LIFESCIENCES LIMITED	+12.49%	290M		C+
CORTEVA, INC.	+19.30%	39.89B		C
PHOSAGRO	-.--%	11.22B	-	B+
FMC CORPORATION	-1.90%	7.72B		A
PI INDUSTRIES LIMITED	+2.38%	6.54B		B-
ICL GROUP LTD	-5.50%	5.97B		B+
OCI N.V.	-4.27%	5.7B		B
THE FERTILISERS AND CHEMICALS TRAVANCORE LIMITED	-11.80%	5.52B	-	C-
YUNNAN YUNTIANHUA CO., LTD.	+29.81%	5.13B		B-
UPL LIMITED	-15.99%	4.44B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes